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Background: Systemic insufﬁciency occurred in cystic ﬁbrosis (CF) and absence
of complete genotype/phenotype correlation especially with reference to CF lung
disease indicates that Cystic Fibrosis Transmembrane Regulator (CFTR) protein
play also other than chloride channel function in the cell. Observed in CF retardation
in the Na+ ions trafﬁcking through the Epithelial Sodium Channel (ENaC) channel
is the results of disturbances in interaction between CFTR and ENaC. It has the
effect on the composition of the airway surface liquid and the mucociliary clearance
in the airways.
Objectives: The aim of the study was to check whether ENaC/CFTR genotype may
predispose to CF phenotype
Patients and Methods: Using sequencing analysis (ABI PRISM 3730, Applied
Biosystems Inc, CA, USA) we screened for mutation in SCNN1a, SCNN1b and
SCNN1W genes, encoded three subunit of ENaC in 30 patients with bronchiectasis,
elevated sweat chloride (<60mmol/L) and with only one or no mutated CFTR allele
known after sequencing of 27 CFTR exons and MLPA analysis (Multiplex Ligation-
dependent Probe Assay (P091; MRC-Holland, Amsterdam, The Netherlands).
Results: More than two-fold signiﬁcant increase in incidence of ENaC mutations
was observed in patients (27%) compared to controls (12%). Moreover the most
frequent in patients was 55+5G>C (p.W493R) in SCNN1a (14%). This mutation is
known to increase ENaC activity four-fold and might contribute to CF phenotype.
Conclusions: Presence of ENaC mutations in patients with clinical CF and
incomplete CFTR genotype predispose to CF phenotype. It indicates polygenic
mechanism of the disease.
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Objectives: A difﬁculty in diagnosis and treatment of CF is the great phenotypic
variability arising from a combination of environmental, stochastic and modiﬁer
gene effects.
It has been proposed that genes interacting with CFTR and ENaC are potential
modiﬁers. Therefore, we are currently assessing the impact of SNPs of several
interacters on CF disease outcome.
Methods: SNPs that potentially alter gene function and have an allele frequency
>10% were genotyped in 95 well-characterized F508del homozygous CF patients.
Linear mixed-effect model (LMM) analysis was used to assess the relationship
between sequence variants and the repeated measurements of lung function param-
eters.
Results: In total we genotyped 78 SNPs in SNAP-23, PPP2R4, PPP2R5E,
PPP2R1A, Nedd4−2, Aha1, AnxA5, PRSS8, CRT and CK-19. Of these SNPs 42
showed an allele frequency <10% and were therefore excluded. 29 SNPs were
genotyped in all 95 patients.
Statistical analysis indicated strong association for one SNP in PPP2R4 with the
lung clearance index (LCI) (p< 0.01) and the speciﬁc effective airway resistance
(sReff) (p< 0.001). In addition, one SNP in AnxA5 and two SNPs in CK-19 showed
association with sReff (p< 0.001 and p< 0.01 respectively) and one SNP in SNAP-
23 with the maximal expired ﬂow at 50% forced vital capacity (FEF50) (p< 0.01)
and the volume of trapped gas (VTG) (p< 0.001).
Conclusion: Our preliminary ﬁndings indicate that direct interacters with CFTR
such as AnxA5, SNAP-23 and PPP2R4 may modify CF phenotypes by inﬂuencing
channel activity, whereas CK-19 may modulate CFTR maturation. Further studies
are needed to conﬁrm and verify these effects.
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From October 2009 to December 2010, 104 455 newborns have been examined
according to new nationwide IRT/DNA/IRT protocol. 965 (0.92%) newborns had
IRT levels above 65 ng/ml (99th percentile) and among those, 16 CF patients were
discovered. 32 or 50 most common CF causing alleles are determined by Elucigene
CF-EU1™ resp. CF-EU2™ assay (Tepnel). Two cases of false negativity appeared
during testing period: 1 case with meconium ileus and 1 case with rare mutations.
Both patients were detected by parallel IRT/PAP/ST+DNA protocol that has been
effective from August 2009 to December 2010. Total of 115 540 newborns has been
tested and 257 (0.22%) newborns had suspective results (IRT levels between 50.0–
100.0 with PAP 1.8 or IRT levels 100.0 and PAP 1.0, all ng/ml) among those
15 CF patients were discovered. Five patients were found false negative (identiﬁed
by IRT/DNA/IRT). Our data interestingly showed that IRT/DNA/IRT protocol has
better efﬁciency − less cases of false negativity.
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